Related Experiment Video

Updated: Jun 27, 2026

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks
09:18

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks

Published on: December 2, 2022

Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa

Tamara L Meragelman1, Dominic A Scudiero, R Eric Davis

  • 1Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland, USA.

Journal of Natural Products
|December 20, 2008
PubMed

Insights

Cryptocarya rugulosa extract inhibits cancer-promoting NF-kappaB signaling. Active compounds, rugulactone and cryptocaryone, show potential for developing new cancer therapies targeting the NF-kappaB pathway.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • The nuclear factor-kappaB (NF-kappaB) signaling pathway is frequently overactive in various cancers, making it a significant therapeutic target.
  • Inhibitor of kappa B (IkappaB) is a key regulator of NF-kappaB activity, and its stability is crucial for controlling the pathway.

Purpose of the Study:

  • To investigate the potential of Cryptocarya rugulosa plant extract in inhibiting constitutive NF-kappaB activity.
  • To identify the specific compounds within the extract responsible for this inhibitory effect.

Main Methods:

  • A cell-based assay was employed to measure the stability of IkappaB, serving as an indicator of NF-kappaB activity.
  • Organic solvent extracts of Cryptocarya rugulosa were tested on human lymphoma cell lines.

Main Results:

  • The plant extract demonstrated inhibition of constitutive NF-kappaB activity in human lymphoma cells.
  • Two active compounds were identified: a novel alpha-pyrone named rugulactone and the known compound cryptocaryone.
  • Rugulactone exhibited greater potency, inducing IkappaB up to 5-fold at 25 microg/mL.

Conclusions:

  • Cryptocarya rugulosa contains compounds that can effectively inhibit the NF-kappaB signaling pathway.
  • Rugulactone and cryptocaryone are promising candidates for further research and development of novel cancer therapeutics targeting NF-kappaB.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...